Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: A practice standard for Canadian nurses
<p class="p1">Azacitidine (5-azacytidine, VIDAZA<span class="s1">®</span>) is a disease-modifying agent that improves survival, reduces transfusion dependence, and reduces progression to acute myeloid leukemia in patients with higher risk myelodysplastic syndrom...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pappin Communications
2012-11-01
|
| Series: | Canadian Oncology Nursing Journal |
| Online Access: | https://canadianoncologynursingjournal.com/index.php/conj/article/view/112 |